In a year marked by new geopolitical and macroeconomic challenges, ProBioGen was able to carry on its rapid growth trajectory by completing a significantly increased number of projects. To support this influx of activities, ProBioGen recruited more than 80 new talents to close 2022 with over 300 employees and moved on in its full digital transformation process aiming at making IT not only a supporting operative function but also a decisive function in the innovation process.

"I am proud of the solid performance ProBioGen delivered in 2022, reaching new heights after an already very successful 2021. I would like to warmly thank all employees for their dedication and hard work which rendered this possible. I also believe that the 2030 Strategic Roadmap we developed in the second half of 2020 has put ProBioGen in the right direction and proven its resilience in difficult times", said Dr. Lutz Hilbrich, Chief Executive Officer at ProBioGen and MiGenTra.

The strong growth is attributable to numerous new customer projects as well as to an increased repeat business with highly satisfied customers. According to customer feedback, ProBioGen's deep scientific expertise as well as the flexible project approach make the company stand out.

Looking at 2023, ProBioGen will keep investing for its future despite a continued gloomy global economic outlook, focusing its attention to broadening its service and technology offering to meet the needs of a broader base of customers and further enhance its competitive edge.